99
Participants
Start Date
March 24, 2022
Primary Completion Date
March 7, 2023
Study Completion Date
March 7, 2023
CV2CoV (2 µg)
Study vaccine was administered as a single intramuscular injection.
CV2CoV (4 µg)
Study vaccine was administered as a single intramuscular injection.
CV2CoV (8 µg)
Study vaccine was administered as a single intramuscular injection.
CV2CoV (12 µg)
Study vaccine was administered as a single intramuscular injection.
CV2CoV (16 µg)
Study vaccine was administered as a single intramuscular injection.
CV2CoV (20 µg)
Study vaccine was planned to be administered intramuscularly. No vaccine was administered in the CV2CoV (20 µg) Group, since there were no participants enrolled in it.
GSK Investigational Site, Hallandale
MD Clinical - Velocity, Hallandale
GSK Investigational Site, Miami
Suncoast Research Group LLC - ERN-PPDS, Miami
GSK Investigational Site, Palm Springs
Accel Research Sites, Lakeland
GSK Investigational Site, Cleveland
Velocity Clinical Research - Cleveland, Cleveland
Affinity Health Corp, Oak Brook
GSK Investigational Site, Oak Brook
GSK Investigational Site, Norman
Lynn Institute of Norman - ERN - PPDS, Norman
GSK Investigational Site, Oklahoma City
Lynn Health Science Institute, Oklahoma City
Research Your Health - Elite, Plano
GSK Investigational Site, Dallas
DM Clinical - Cyfair Clinical Research Center, Tomball
GSK Investigational Site, Tomball
GSK Investigational Site, Cedar Park
GSK Investigational Site, West Jordan
Velocity Clinical Research - Salt Lake City - Jordan Valley-ERN-PPDS, West Jordan
Lynn Institute of Denver - ERN, Aurora
GSK Investigational Site, Lakeland
GSK Investigational Site, Dallas
Lead Sponsor
Collaborators (1)
CureVac
INDUSTRY
GlaxoSmithKline
INDUSTRY